Medical device company LeMaitre Vascular (NASDAQ: LMAT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 15% year on year to $64.23 million. Guidance for next quarter’s revenue was optimistic at $62.2 million at the midpoint, 2.1% above analysts’ estimates. Its GAAP profit of $0.60 per share was 5.8% above analysts’ consensus estimates.

Is now the time to buy LMAT? Find out in our full research report (it’s free).

StockStory’s Take

LeMaitre’s second quarter saw a strong market reaction, reflecting outperformance across key segments and positive investor sentiment. Management attributed the results to robust sales growth in catheters and grafts, with notable contributions from international markets such as EMEA and Asia-Pacific. CEO George LeMaitre cited the successful European launch of Artegraft and increased adoption of RestoreFlow, particularly in cardiac applications, as primary growth drivers. The quarter also benefited from higher average selling prices and improved manufacturing efficiency, supporting both top-line and margin expansion.

Looking ahead, LeMaitre’s guidance reflects confidence in continued momentum from international product launches and regulatory progress. Management pointed to anticipated approvals for Artegraft in additional countries, a RestoreFlow launch in Europe, and the ongoing direct sales expansion as central to future growth. CFO Dorian LeBlanc highlighted that operating expenses are expected to decrease in the second half of the year, while CEO George LeMaitre emphasized the significance of new market entries and product pipeline advancements, stating, “2025 is shaping up to be another year of healthy sales and profit growth.”

Key Insights from Management’s Remarks

Management credited the quarter’s performance to robust demand for core products, international expansion, and operational improvements, while also highlighting the impact of product launches and evolving regulatory milestones.

• International Artegraft launch exceeds expectations: The European and South African rollout of Artegraft delivered stronger-than-anticipated sales, with management projecting over $2 million in international sales for the full year, and approvals in new geographies such as Canada, Korea, and Singapore expected by 2026.
• RestoreFlow gaining traction: RestoreFlow’s adoption in cardiac applications grew significantly, with 61% unit growth in cardiac allografts, driven by increased focus from U.S. sales teams and rising interest in the Ross procedure. Management is preparing for upcoming European launches, supported by a new distribution facility in Dublin.
• Sales force expansion supports growth: The addition of 23 sales professionals and expansion of the direct sales model in Europe, including new initiatives in Portugal and the Czech Republic, contributed to both volume and price growth, with the company ending the quarter with 164 sales reps.
• Pricing and niche strategy: Price increases accounted for 8% of organic growth, enabled by LeMaitre’s strong positions in niche markets where the company can exercise pricing power. Management indicated this cadence is likely to continue, though future hikes depend on market conditions.
• Operational efficiency and margin stability: Higher manufacturing efficiency, favorable product mix, and the completion of regulatory projects (such as MDR compliance) helped maintain strong gross and operating margins, despite increased compensation and investment in international expansion.

Drivers of Future Performance

LeMaitre’s updated outlook is built on accelerating international product adoption, continued direct sales expansion, and a robust pipeline of regulatory approvals.

• New product approvals and launches: Management expects near-term growth from the expansion of Artegraft into additional global markets and the anticipated RestoreFlow approval in Europe. These launches are positioned to tap into sizable addressable markets and build on early adoption momentum.
• Sales organization and geographic reach: The expanded sales force and direct-to-hospital strategies in underpenetrated international markets are expected to drive further volume growth and higher average selling prices, particularly outside the U.S.
• Operational and regulatory risks: Management noted potential headwinds from tariff adjustments, supply constraints for allografts, and the need for country-specific regulatory approvals, especially in Europe. While operating expenses are set to decline in the second half of the year, investments in new market entries and inventory build-outs may introduce variability.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will focus on (1) the pace of Artegraft’s adoption in new international markets and the success of ongoing regulatory filings; (2) progress and market response to the pending RestoreFlow launch in Europe, including new distribution capabilities; and (3) sustained organic growth from the expanded sales organization. Additional signposts include updates on regulatory approvals in Asia-Pacific and the impact of evolving tariff and trade dynamics.

LeMaitre currently trades at $94.30, up from $85.94 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.